Concord Biotech Ltd.’s shares rose by 5% following the U.S. Food and Drug Administration’s approval of its Abbreviated New Drug Application for Tofacitinib Tablets, available in 5 mg and 10 mg strengths. This medication is used to treat several chronic and autoimmune conditions, including rheumatoid arthritis and ulcerative colitis, and the U.S. market for Tofacitinib is valued at around $500 million. The approval aligns with the company’s growth strategy to expand its product offerings and commercial presence in both the U.S. and international markets. Following the news, shares are trading at ₹1,334.7, reflecting a 25% increase over the past eight sessions.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.cnbctv18.com/market/concord-biotech-share-price-usfda-approval-tofacitinib-tablets-500-million-drug-us-market-impact-ws-l-19922836.htm
